Study protocol of a phase 1 clinical trial establishing the safety of intrapleural administration of liposomal curcumin: curcumin as a palliative treatment for malignant pleural effusion (IPAL-MPE)

Abstract

IntroductionThis is a phase 1, open-label, single-centre, uncontrolled, dose-escalation study to evaluate the feasibility, tolerability and pharmacokinetic profiles of a single dose of liposomal curcumin, administered via an existing tunnelled indwelling pleural catheter (TIPC) directly to the tumour site in individuals with diagnoses of malignant pleural effusion. Primarily, we aim to determine a maximum tolerated dose of liposomal curcumin administered via this method.Methods and analysisWe will use a 3+3 expanded cohort for predefined dose-escalation levels or until a predefined number of dose-limiting toxicities are reached. Participants will be administered a single dose of liposomal curcumin (LipoCurc, SignPath Pharma) via their existing TIPC as a sequential enrolling case series with the following dose cohorts: 100, 200 and 300 mg/m2. Primary endpoints are determination of the maximum tolerated dose within the predetermined dose range, and determination of the feasibility of intrapleural administration of liposomal curcumin via an existing TIPC. Secondary endpoints include determination of the safety and tolerability of intrapleural administration of liposomal curcumin, median overall survival, effects on quality of life and on feelings of breathlessness, and the pharmacokinetics and concentrations of curcumin from the plasma and the pleural fluid. Important inclusion criteria include age ≥18 years, an existing TIPC, a pleural biopsy or pleural fluid cytology-proven diagnosis of malignant pleural effusion and for whom no antitumour therapy of proven benefit is available or has been previously declined, eastern cooperative group performance status <2.Ethics and disseminationThe study protocol has been approved by the Southern Adelaide Local Health Network Human Research Ethics Committee (HREC) (approval number: HREC/20/SAC/11). Study results will be published in peer-reviewed journals, and presented at conferences, in field of medical oncology and respiratory medicine.Trial registration numberACTRN12620001216909.Protocol version numberV.1.0.

Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological review

“… Questionnaire Number of times used as instrument Associated trials EORTC QLQ-C30 (Quality of life of cancer patients) 14 8 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 EQ-5D (Generic quality of life) 5 28 , 38 , 39 , 40 , 41 EPIC 4 42 , 43 , 44 , 45 IPSS 3 42 , 44 , 46 AUA 3 43 , 44 , 47 M.D. Anderson Dysphagia Inventory 2 8 , 28 CLAS1 2 48 , 49 CLAS2 2 48 , 49 CLAS3 2 48 , 49 FACT-G (General) 2 <...…”

Mechanism insights of curcumin and its analogues in cancer: An update

“…Thus, investigators are making various efforts to overcome these limitations viz. advanced drug delivery systems including liposomes, nanoparticles, and defined phospholipid complexes developed using a variety of synthetic or natural proteins, lipids, or polymers have resulted in better bioavailability and stability of curcumin and its analogues (Dhule et al, 2014; Hocking et al, 2021; Luo et al, 2021; Tomeh et al, 2019). Similarly, the synthesis of new analogues of curcumin is underway to attain desired pharmacokinetic and pharmacodynamic profiles in preclinical studies (Bisht et al, 2016; Luo et al, 2021).…”